Enrique Sanz-Garcia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Enrique Sanz-Garcia has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Anna Spreafico
Division of Medical Oncology, the Princess Margaret Cancer Centre/University of Toronto, Canada
4 shared publications - Ali Hosni
Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, ON M5G 2C4, Canada
3 shared publications - Andrew McPartlin
Radiation Medicine Program, Princess Margaret Cancer Centre, University of Toronto, 610 University Ave, Toronto, ON M5G 2M9, Canada
3 shared publications - B.C. John Cho
Department of Radiation Oncology, the Princess Margaret Cancer Centre/University of Toronto, Canada
3 shared publications - Ezra Hahn
Department of Radiation Oncology, Princess Margaret Cancer Centre/University of Toronto, Toronto, Canada
3 shared publications - John Waldron
Department of Radiation Oncology, the Princess Margaret Cancer Centre/University of Toronto, Canada; Department of Otolaryngology - Head & Neck Surgery, the Princess Margaret Cancer Centre/University of Toronto, Canada
3 shared publications
Latest Publications
- Open Access
- 29 April 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (9) , 3979
Pan-Cancer Pre-Treatment ctDNA Detection Using a Highly Sensitive Tumor-Informed Assay
Circulating tumor DNA (ctDNA) has many potential applications in the management of cancer, including detection, monitoring, and treatment response assessment. This study evaluates pre-treatment ctDNA detection in a single-institution pan-cancer cohort using a highly sensitive tumor-informed ctDNA assay. Participant samples were collected at the University Health Network across six study cohorts. A total of 273 patients with stage II-IV cancers spanning 16 tumor types were analyzed using a personalized tumor-informed assay (RaDaR®). Harmonized methods were employed to mitigate the impact of variables known to influence ctDNA detection and its quantification. Pre-treatment ctDNA was detected in 83% of participants (226/273) across all stages and cancer types. Detection rates varied by clinical characteristics, including cancer type and stage; ctDNA was detected in 100% of stage IV metastatic recurrent high-grade serous ovarian cancer (HGSOC) patients (n = 8/8) and 54% of stage IV melanoma patients (n = 6/11). The median estimated variant allele fraction (eVAF) across all patients with a positive ctDNA result was 0.25% (range: 0.000029–37.7%), varied by tumor type and increased with cancer stage. A total of 11% of positive samples (24/226) had an eVAF of <0.01%. This pan-cancer ctDNA analysis using a highly sensitive assay reveals high detection rates overall, including ~10% at low levels (<0.01% eVAF), offering a reference for future clinical ctDNA applications and furthering our understanding of factors influencing ctDNA measurements.
- 29 April 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (9) , 3979
Open AccessPan-Cancer Pre-Treatment ctDNA Detection Using a Highly Sensitive Tumor-Informed Assay
Circulating tumor DNA (ctDNA) has many potential applications in the management of cancer, including detection, monitoring, and treatment response assessment. This study evaluates pre-treatment ctDNA detection in a single-institution pan-cancer cohort using a highly sensitive tumor-informed ctDNA assay. Participant samples were collected at the University Health Network across six study cohorts. A total of 273 patients with stage II-IV cancers spanning 16 tumor types were analyzed using a personalized tumor-informed assay (RaDaR®). Harmonized methods were employed to mitigate the impact of variables known to influence ctDNA detection and its quantification. Pre-treatment ctDNA was detected in 83% of participants (226/273) across all stages and cancer types. Detection rates varied by clinical characteristics, including cancer type and stage; ctDNA was detected in 100% of stage IV metastatic recurrent high-grade serous ovarian cancer (HGSOC) patients (n = 8/8) and 54% of stage IV melanoma patients (n = 6/11). The median estimated variant allele fraction (eVAF) across all patients with a positive ctDNA result was 0.25% (range: 0.000029–37.7%), varied by tumor type and increased with cancer stage. A total of 11% of positive samples (24/226) had an eVAF of <0.01%. This pan-cancer ctDNA analysis using a highly sensitive assay reveals high detection rates overall, including ~10% at low levels (<0.01% eVAF), offering a reference for future clinical ctDNA applications and furthering our understanding of factors influencing ctDNA measurements.
- Open Access
- 13 February 2026
- Published by Springer Nature in npj Precision Oncology
- Vol. 10 (1)
Clinical validation of a tissue-agnostic genome-wide methylome enrichment assay to monitor response to pembrolizumab
Immunotherapy has significantly improved the treatment of metastatic solid tumors; however, detecting early signs of response to enable timely intervention for resistant tumors remains challenging. A blood-only circulating tumor DNA (ctDNA) test may provide a rapid assessment of tumor response without reliance on matched tumor tissue. We applied a tissue-agnostic, genome-wide methylation enrichment assay, based on cell-free methylated DNA immunoprecipitation and high-throughput sequencing (cfMeDIP-seq), to plasma samples from patients in a phase 2 trial evaluating pembrolizumab across multiple solid tumors (NCT02644369). A decrease in ctDNA from baseline to pre-cycle 3 was significantly associated with higher objective response and clinical benefit rates and longer progression-free and overall survival in univariate analyses, with these associations remaining significant in multivariable models except for overall survival. These results validate a commercial-grade, tissue-agnostic plasma cfDNA methylation platform for immunotherapy response monitoring, which may facilitate earlier, more informed treatment decisions and improve patient outcomes.
- 13 February 2026
- Published by Springer Nature in npj Precision Oncology
- Vol. 10 (1)
Open AccessClinical validation of a tissue-agnostic genome-wide methylome enrichment assay to monitor response to pembrolizumab
Immunotherapy has significantly improved the treatment of metastatic solid tumors; however, detecting early signs of response to enable timely intervention for resistant tumors remains challenging. A blood-only circulating tumor DNA (ctDNA) test may provide a rapid assessment of tumor response without reliance on matched tumor tissue. We applied a tissue-agnostic, genome-wide methylation enrichment assay, based on cell-free methylated DNA immunoprecipitation and high-throughput sequencing (cfMeDIP-seq), to plasma samples from patients in a phase 2 trial evaluating pembrolizumab across multiple solid tumors (NCT02644369). A decrease in ctDNA from baseline to pre-cycle 3 was significantly associated with higher objective response and clinical benefit rates and longer progression-free and overall survival in univariate analyses, with these associations remaining significant in multivariable models except for overall survival. These results validate a commercial-grade, tissue-agnostic plasma cfDNA methylation platform for immunotherapy response monitoring, which may facilitate earlier, more informed treatment decisions and improve patient outcomes.
- Open Access
- 15 July 2025
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 214, 104841
Navigating the challenges of immunotherapy as a neoadjuvant treatment for locally advanced squamous cell carcinoma of the head and neck: A review of the evidence from the literature
- 15 July 2025
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 214, 104841
Open AccessNavigating the challenges of immunotherapy as a neoadjuvant treatment for locally advanced squamous cell carcinoma of the head and neck: A review of the evidence from the literature
- Open Access
- 24 May 2025
- Published by Springer Nature
- p. 89-110
Precision Medicine Beyond Genomics
Precision oncology based on specific genomic alterations has become a standard in the management of some tumours. Different studies (NCI-MATCH, TAPUR, DRUP, or MyPathway) have used a broader approach, testing multiple genes at the same time and assigning targeted therapies in basket trials. These studies showed some encouraging results supporting the potential use of next-generation sequencing in precision oncology. However, the application in head and neck cancer (except for salivary gland tumours) is still limited. The field is moving quickly into other approaches such as whole genome and transcriptome analysis. Transcriptome analyses have successfully helped in treatment decisions in some patients within prospective studies (WINTHER, POG). In head and neck cancer, gene expression signatures evaluating hypoxia or predicting anti-epidermal growth factor receptor (EGFR) therapy response, have been explored. As immunotherapy has become a standard in the treatment of squamous head and neck carcinoma, ribonucleic acid (RNA)-based immune signatures have been proposed to select those patients with higher probabilities of response. All these analyses are based on bulk transcriptomics. Nevertheless, understanding the role of each cell and its spatial configuration could be useful in precision oncology. In this sense, single-cell RNA sequencing could provide a better understanding of the different cell populations and their activities and potentially predict treatment response. Other immune-related biomarkers such as the T-cell receptor characteristics could provide an improved insight into the resistance to immunotherapy in patients with head and neck cancer. Non-coding genome analysis may contribute to a better understanding of the mechanisms of resistance or sensitivity to drugs and aid in discovering new therapeutic targets. However, most of the current precision medicine approaches rely on tumour tissue. This is a limitation for a broader applicability due to tumor heterogeneity and the need for tumour biopsies. Easy-to-access biomarkers such as circulating tumour deoxyribonucleic acid (ctDNA) could overcome both limitations as well as provide a more dynamic overview of the disease. Further understanding of molecular biology and tumour microenvironment including multi-institution collaborative initiatives and prospective studies is needed to translate these findings into our clinical practice.
- 24 May 2025
- Published by Springer Nature
- p. 89-110
Open AccessPrecision Medicine Beyond Genomics
Precision oncology based on specific genomic alterations has become a standard in the management of some tumours. Different studies (NCI-MATCH, TAPUR, DRUP, or MyPathway) have used a broader approach, testing multiple genes at the same time and assigning targeted therapies in basket trials. These studies showed some encouraging results supporting the potential use of next-generation sequencing in precision oncology. However, the application in head and neck cancer (except for salivary gland tumours) is still limited. The field is moving quickly into other approaches such as whole genome and transcriptome analysis. Transcriptome analyses have successfully helped in treatment decisions in some patients within prospective studies (WINTHER, POG). In head and neck cancer, gene expression signatures evaluating hypoxia or predicting anti-epidermal growth factor receptor (EGFR) therapy response, have been explored. As immunotherapy has become a standard in the treatment of squamous head and neck carcinoma, ribonucleic acid (RNA)-based immune signatures have been proposed to select those patients with higher probabilities of response. All these analyses are based on bulk transcriptomics. Nevertheless, understanding the role of each cell and its spatial configuration could be useful in precision oncology. In this sense, single-cell RNA sequencing could provide a better understanding of the different cell populations and their activities and potentially predict treatment response. Other immune-related biomarkers such as the T-cell receptor characteristics could provide an improved insight into the resistance to immunotherapy in patients with head and neck cancer. Non-coding genome analysis may contribute to a better understanding of the mechanisms of resistance or sensitivity to drugs and aid in discovering new therapeutic targets. However, most of the current precision medicine approaches rely on tumour tissue. This is a limitation for a broader applicability due to tumor heterogeneity and the need for tumour biopsies. Easy-to-access biomarkers such as circulating tumour deoxyribonucleic acid (ctDNA) could overcome both limitations as well as provide a more dynamic overview of the disease. Further understanding of molecular biology and tumour microenvironment including multi-institution collaborative initiatives and prospective studies is needed to translate these findings into our clinical practice.
- 21 April 2025
- Published by Elsevier in Oral Oncology
- Vol. 165, 107299
Outcomes following IMRT alone in head and neck squamous cell carcinoma ordinarily managed with concurrent chemo-radiotherapy
- 21 April 2025
- Published by Elsevier in Oral Oncology
- Vol. 165, 107299
Outcomes following IMRT alone in head and neck squamous cell carcinoma ordinarily managed with concurrent chemo-radiotherapy
- 23 August 2024
- Published by Elsevier in Oral Oncology
- Vol. 158, 107007
The prognostic value of image-identified extranodal extension in laryngeal and hypopharyngeal carcinoma following definitive (chemo-)radiotherapy
- 23 August 2024
- Published by Elsevier in Oral Oncology
- Vol. 158, 107007
The prognostic value of image-identified extranodal extension in laryngeal and hypopharyngeal carcinoma following definitive (chemo-)radiotherapy
- Open Access
- 28 March 2023
- Published by Springer Nature
- p. 305-314
Targeting Molecular Residual Disease Using Novel Technologies and Clinical Trials Design in Head and Neck Squamous Cell Cancer
High-risk human papillomavirus (HPV)-related and most cases of HPV-negative locoregionally advanced head and neck squamous cell carcinoma (LA-HNSCC) have substantial risks of relapse despite definitive therapy, and thus represent conditions of unmet clinical need. The ability now exists to detect molecular residual disease (MRD) in these patients post-definitive treatment such as surgery or (chemo)radiotherapy using novel and highly sensitive and specific technologies to measure cancer-derived circulating biomarkers. The positive and negative predictive values of these assays to forecast cancer recurrence, as well as the lead time of circulating tumor DNA (ctDNA) detection before clinical relapse, are relevant as these parameters rationalize the design of clinical trials for cancer interception in the MRD setting. Currently, there is evidence that interception in the MRD setting yields benefit in clinical outcome in some cancers, but such data do not yet exist in LA-HNSCC and will require prospective testing via clinical trials.
- 28 March 2023
- Published by Springer Nature
- p. 305-314
Open AccessTargeting Molecular Residual Disease Using Novel Technologies and Clinical Trials Design in Head and Neck Squamous Cell Cancer
High-risk human papillomavirus (HPV)-related and most cases of HPV-negative locoregionally advanced head and neck squamous cell carcinoma (LA-HNSCC) have substantial risks of relapse despite definitive therapy, and thus represent conditions of unmet clinical need. The ability now exists to detect molecular residual disease (MRD) in these patients post-definitive treatment such as surgery or (chemo)radiotherapy using novel and highly sensitive and specific technologies to measure cancer-derived circulating biomarkers. The positive and negative predictive values of these assays to forecast cancer recurrence, as well as the lead time of circulating tumor DNA (ctDNA) detection before clinical relapse, are relevant as these parameters rationalize the design of clinical trials for cancer interception in the MRD setting. Currently, there is evidence that interception in the MRD setting yields benefit in clinical outcome in some cancers, but such data do not yet exist in LA-HNSCC and will require prospective testing via clinical trials.